



HAL
open science

Carbon quantum dots as a dual platform for the inhibition and light-based destruction of collagen fibers: implications for the treatment of eye floaters

Alexandre Barras, Félix Sauvage, Inès de Hoon, Kevin Braeckmans, Dawei Hua, Gaëtan Buvat, Juan C Fraire, Christophe Lethien, J. Sebag, Michael Harrington, et al.

► To cite this version:

Alexandre Barras, Félix Sauvage, Inès de Hoon, Kevin Braeckmans, Dawei Hua, et al.. Carbon quantum dots as a dual platform for the inhibition and light-based destruction of collagen fibers: implications for the treatment of eye floaters. *Nanoscale Horizons*, 2021, 6 (6), pp.449-461. 10.1039/D1NH00157D . hal-03209389

HAL Id: hal-03209389

<https://hal.science/hal-03209389v1>

Submitted on 27 Apr 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Carbon quantum dots as a dual platform for the inhibition and light-based destruction of collagen fibers: implications for the treatment of eye floaters

Alexandre Barras,^{1**} Félix Sauvage,^{2**} Inès de Hoon,^{1,2} Kevin Braeckmans,² Dawei Hua,² Gaëtan Buvat,¹ Juan C. Fraire,² Christophe Lethien,¹ J. Sebag,^{3,4} Michael Harrington⁵, Amar Abderrahmani,¹ Rabah Boukherroub,¹ Stefaan De Smedt,^{2*} Sabine Szunerits^{1*}

¹*Univ. Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, F-59000 Lille, France*

²*Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.*

³*VMR Institute for Vitreous Macula Retina, Huntington Beach, California 92647, United States*

⁴*Doheny Eye Institute/UCLA, Los Angeles, California 90033, United States*

⁵*Huntington Memorial Research Institute, Pasadena, CA, USA*

Abstract

Common in myopia and aging, vitreous opacities arise from clumped collagen fibers within the vitreous body that cast shadows on the retina, appearing as ‘floaters’ to the patient. Vitreous opacities degrade contrast sensitivity function and can cause significant impairment in vision-related quality-of-life, representing an unmet and underestimated medical need. One therapeutic approach could be the use of versatile light-responsive nanostructures which (i) interfere with the formation of collagen fibers and /or (ii) destroy aggregates of vitreous collagen upon pulsed-laser irradiation at low fluences. In this work, the potential of positively and negatively charged carbon quantum dots (CQDs) to interfere with the aggregation of type I collagen is investigated. We demonstrate that fibrillation of collagen I is prevented most strongly by positively charged CQDs (CQDs-2) and that pulsed-laser illumination allowed to destroy type I collagen aggregates and vitreous opacities (as obtained from patients after vitrectomy) treated with CQDs-2.

**equal contribution

*To whom correspondence should be send to: Stefaan.Desmedt@UGent.be or sabine.szunerits@univ-lille.fr (SS)

Keywords: Vitreous floaters, carbon quantum dots (CQDs), collagen fibers, pulsed-laser, ophthalmology, fibrillation.

1. Introduction

Opacities in the vitreous body are one of the most common causes of severe impairment in ocular vision. Vitreous opacities are characterized by floating objects inside the vitreous body, which can result from several origins including myopia, infection, diabetic retinopathy, aging and eye injury. Vitreous is a highly hydrated gel-like structure (>98% water), which is maintained by a diluted network of long, thin collagen fibrils. Individual collagen fibrils are normally spaced apart by hyaluronan, an anionic, non-sulfated glycosaminoglycan (polysaccharide), which attracts water and generates a swelling pressure that inflates the gel. Vitreous collagen fibrils are heterotypic in composition, containing type IX collagen being regularly distributed along the fibril surfaces;¹ rope-like fibrils of collagen types II surrounding a central core of hybrid V/XI, with type II collagen predominating.² Type IX collagen has chondroitin sulfate glycosaminoglycan chains attached to it which extend away from the fibril surfaces and space apart the collagen fibrils, thereby preventing fibril aggregation.³ Vitreous opacities and the degeneration of the vitreous body result from several interconnected mechanisms including the progressive cross-linking of individual collagen fibrils and their aggregation, and finally, liquefaction.⁴ Liquefaction is a physicochemical degenerative change that disrupts the homogeneity of the gel vitreous and is characterized by the dissociation of hyaluronan from collagen. Thus, vitreous progressively liquefies as the collagen fibril aggregates and HA dissociates from collagen drawing water with it to form liquid vitreous. Collagen becomes concentrated in some areas of the gel, while other parts of the vitreous body are devoid of collagen fibrils forming liquid compartments.⁵ Another proposed mechanism for vitreous liquefaction is that collagen fibrils are fragmented.⁶ It is believed that type IX collagen shields type II collagen and prevents fusion between fibrils.³ Loss of type IX collagen results in type II collagen becoming increasingly exposed, predisposing to fusion of adjacent fibrils on contact. In both cases, when the aggregates are sufficiently large, they are visible as vitreous opacities resulting in degradation of contrast sensitivity function^{4, 7} with a negative impact on the quality of life.^{8, 9} Other mechanisms of vitreous liquefaction can be considered, including enzymatic liquefaction and oxidative stress-induced liquefaction.¹⁰

The treatment of vitreous opacification relies on its origin. However, in case of treatment failure, the only curative treatment for removing floaters remains vitrectomy (i.e. a surgical removal of vitreous through small openings in the pars plana)^{11, 12} or by Nd:YAG laser treatment.¹³ However, treatment with the Nd:YAG laser has relatively little efficacy¹⁴ and sometimes can worsen the eye symptoms. In addition, if the opacities are located too close to the retina, for

safety reasons, laser treatment cannot be achieved. There is a true medical need for searching for safe and non-invasive methods for treating vitreous floaters. Also, non-surgical therapies have been under development, but, pharmacologic vitreolysis has not been designed to address vitreous opacities.^{10, 15, 16} More recently, the use of light absorbing gold nanoparticles (Au NPs) was proposed by some of us as an alternative solution.¹⁷ When coated with hyaluronic acid, after injection in vitreous *ex vivo*, these particles diffuse through vitreous and cluster on the collagenous opacities. Thanks to their photothermal properties, Au NPs heat up in an ultrafast manner when illuminated by a nanosecond pulsed-laser; this leads to the evaporation of the water surrounding the Au NPs and the formation of vapor nanobubbles (VNBs). We showed that VNBs collapsing at the surface of the vitreous opacities provide sufficient mechanical force to ablate them. Importantly, the combined use of the Au NPs and nanosecond laser pulses allowed destruction of the opacities at a laser energy ~ 1000 times lower than typically used in YAG laser therapy. Of note is that pulsed lasers are commonly used in ophthalmology for the treatment of cataract and in corneal surgery.

Carbon-based nanostructures, such as carbon quantum dots (CQDs), offer promising therapeutic potential as they can engage with biological molecules.¹⁸ These nanostructures have proven to be excellent drug carrier due to its good biocompatibility.¹⁹ The easy of introducing functional groups has enabled their application as medical countermeasure to enveloped viruses, including next to herpes simplex virus type 1²⁰ human corneaviruses. The intrinsic fluoresce properties make them well adapted for bio-imaging but allows as well its use in biosensing platforms.¹⁸ One of their applications is the treatment of eye infections with highly positively charged CQDs.²¹ CQDs have also been explored for the treatment of corneal neovascularization²² and to improve retinal angiography.^{23, 24} Motivated by the reported ability of CQDs to prevent human insulin fibrillation,²⁵⁻²⁸ and the potential of CQDs in regulating the aggregation behavior of human islet amyloid polypeptide (hIAPP)²⁹ and by their good light absorbing properties over a wide wavelength spectrum, we aim to investigate (i) the potential of CQDs to inhibit the formation of collagen aggregates and (ii) the combined use of CQDs and pulsed laser light to destroy collagen fibers and vitreous opacities through the generation of VNBs (**Figure 1**).




Figure 1. Carbon quantum dots (CQDs) to inhibit the formation of collagen aggregates (top) and to destroy collagen aggregates by light induced VNBs (bottom).

2. Results and discussion

2.1. One-step microwave-assisted synthesis of aminated and carboxylated fluorescent carbon dots

We have shown previously that a large panel of differently functionalized CQDs can be produced by hydrothermal carbonization of different organic precursors.³⁰ Hydrothermal techniques lead to highly fluorescent CQDs, but long reaction times and high temperature conditions using a close Teflon-line reactor lead too often to a lack of reproducibility and replicability. Alternatively, microwave-assisted synthesis of CQDs is a more reproducible and easier approach due to the on-line monitoring of temperature and pressure in the reaction vessels.^{18, 31} To this end, a rapid synthesis of carboxylic acid-decorated CQDs (CQD-1) using glucosamine as a starting material and an amino acid (β -alanine) as surface a passivating agent was investigated.³² Aminated CQDs (CQD-2) were prepared in a comparable manner from glucosamine hydrochloride and ethylenediamine as a passivating agent (**Figure 2a**).³³ To remove larger precipitates, the CQDs suspension was centrifuged and then dialyzed against water with a final yield of 0.8% and 3.4% for CQD-1 and CQD-2, respectively. CQD-1 exhibit a spherical shape with a primary average diameter of 20.8 ± 6.6 nm (**Table 1**), as determined by AFM (**Figure 2b**). CQD-1 form a “bunch of grapes” in solution and their size reaches up to 50-350 nm in good accordance with the hydrodynamic size recorded by DLS. CQD-2 display a spherical shape with an average diameter of 16.8 ± 6.7 nm (**Table 1**), as determined by AFM

(Figure 2b). Transmission electron microscopy (TEM) observations reveals that the CQDs were almost spherical with an average particle size of ~26 and ~19 nm, respectively, in a good concordance with sizes determined by AFM (**Figure S1**). The amorphous nature of the CQDs was concluded by the absence of clear lattice fringes as well as any clear pattern in the selected area electron diffraction in the TEM microscopy (data not shown).

Table 1: Physico-chemical properties of CQDs.

	CQD-1	CQD-2
ζ / mV	(-) 24.0 ± 1.6	(+) 32.5 ± 0.8
Size determined by AFM / nm	20.8 ± 6.6	16.8 ± 6.7
Hydrodynamic size (intensity)/ nm	389 ± 123 (100%)	10.6 ± 2.3 (63%) 265 ± 199 (29%)
O / at. %	22.8	14.4
N / at. %	5.7	13.7
I _D /I _G ratio	1.94	1.56
Colloidal stability in water	excellent	excellent
Colloidal stability in DMEM	excellent	excellent
Quantum yield (Φ)	0.008	0.002

DMEM = Dulbecco's Modified Eagle's




The chemical composition of the carbon dots was assessed by X-ray photoelectron spectroscopy (XPS, see survey in SI, **Figure S2**). The C_{1s} high resolution XPS spectra of the CQDs depict different carbon features (**Figure 2c**). In the case of CQD-1, the high-resolution spectrum of the C_{1s} reveals the presence of five peaks ascribed to C=C (283.8 eV), C–C/C–H (285.0 eV), C–N/C–O (286.8 eV), C=O (287.9 eV) and –O–C=O (289.2 eV). The presence of carbonyl and carboxylic functions is additionally validated by the presence of a band at 530.7 eV (C=O) in the O_{1s} high resolution spectrum, next to 531.5 eV (C–O). The N_{1s} high resolution spectrum can be curve-fitted with bands at 398.3 eV (pyridinic C=N–C), 399.1 eV (pyrrolic N–H) and 400.3 eV (graphite-like structure N–C₃). In case of CQD-2 (**Figure 2d**), the high-resolution spectrum of the C_{1s} can be deconvoluted with five peaks assigned to C=C (283.9 eV), C–C/C–H (285.0 eV), C–N/C–O (286.1 eV), C=O (287.1 eV) and –O–C=O (288.4 eV). The presence of oxygen functions is also corroborated by the presence of the band at 530.3 eV (C=O) in the O_{1s} high resolution spectrum, next to 531.6 eV (C–O). The N_{1s} high resolution spectrum shows comparable bands as CQDs-1: 398.3 eV (pyridinic C=N–C), 399.2 eV (pyrrolic N–H) and 400.9 eV (graphite-like structure N–C₃). Both CQDs have a variety of polar groups (hydroxyl, carbonyl, carboxyl, amine) present on their surface. The presence of N–C₃ moieties indicates that some nitrogen atoms were incorporated into the carbon framework. The oxygen content in

the CQD-1 and CQD-2 was determined to be 22.8 at. % and 14.4 at. %, respectively. Higher nitrogen content (13.7 at. %) was found in CQD-2 in comparison with CQD-1 (5.7 at. %). Furthermore, the presence of primary amino groups was validated by the ninhydrin reaction test (see SI, **Figure S3**), which allowed estimating a surface coverage of $0.24 \pm 0.2 \text{ mmol g}^{-1}$.

The chemical composition of the CQDs was further investigated by Fourier transform infrared (FT-IR) spectroscopy (**Figure 2e**). The FTIR spectrum of CQD-2 comprises a broad band between $3415\text{-}3425 \text{ cm}^{-1}$ attributed to the O-H/N-H stretching vibrations, while the C-H stretching and bending vibrations are located at 2932 and 1384 cm^{-1} , respectively. The band at 1636 cm^{-1} is due to C=N and C=C bonds of the aromatic structure, and C=O stretching vibration (-NHCO-). Compared to CQD-2, the more intense peaks at 1083 and 1041 cm^{-1} in the FTIR spectrum of CQD-1 are associated with C-O stretching of either the residual carbohydrate or β -alanine. The sharp peak at 1710 cm^{-1} is assigned to the asymmetric stretching vibration of carboxylic acid moieties.³⁴

Typical Raman spectra of CQD-1 and CQD-2 are seen in **Figure 2f**. The observed peaks are typical of sp^2 carbon materials at 1580 cm^{-1} (G-band) and 1378 cm^{-1} (D band), indicating that the material is ordered and graphitic in nature. The fact that the D band is rather broad points towards a disordered structure, keeping in mind that the D-peak is not related to disorder but indirectly to the size of the sp^2 coordinating ring domains. The I_D/I_G ratio is 1.94 for CQD-1 and 1.56 for CQD-2 suggesting large surface disorder and amorphous nature.³⁵

Zeta potential analysis is a source of information in terms of surface functionalities (**Figure S4a**). CQD-1 display a negative zeta potential value ($\zeta = -24.0 \pm 1.6 \text{ mV}$) in pure milli-Q water. The negative surface charge is due to an abundance of deprotonated carboxyl groups on its surface. In contrast, CQD-2 exhibits a positive surface charge with $\zeta = +32.5 \pm 0.8 \text{ mV}$, underlining the presence of NH_3^+ groups. Due to the presence of hydrophilic groups, CQDs were readily dispersible at high concentrations ($> 10 \text{ mg mL}^{-1}$) in pure water or PBS. The dispersion of $250 \mu\text{g mL}^{-1}$ CQDs (**Figure S4b**) in pure water and Dulbecco's Modified Eagle's medium (DMEM) is excellent for both particles. In PBS, the colloidal stability of CQD-2 is reduced and a precipitate is formed after 1 h incubation at $37 \text{ }^\circ\text{C}$.



(d)




Figure 2: (a) Schematic representation of the synthesis of CQD-1 and CQD-2. (b) AFM images of CQD-1 and CQD-2 together with size distribution histograms. (c) XPS analysis of CQD-1: C_{1s}, O_{1s} and N_{1s}. (d) XPS analysis of CQD-2: C_{1s}, O_{1s} and N_{1s}. (e) FT-IR spectra of CQD-1 (red) and CQD-2 (blue). (f) Raman spectra of CQD-1 (red) and CQDs-2 (blue).

The CQDs absorb in the short-wavelength region with a maximum at around 220 nm due to π - π^* transition of C=C and C=N carbon cores with a weak extending tail in the visible region (**Figure 3a**). An additional shoulder at approximately 280 nm is attributed to π - π^* transition of different sp² domains.³⁶ The absorption shoulder at around 306 nm in CQD-1 is due to n- π^* transitions of C=O. This contribution is decreased in CQD-2 due to the high content of ethylenediamine;³⁷ the strong absorption extending from 350 to 600 nm is related to surface passivation of CQDs-2 with ethylenediamine.³⁸

As expected, CQD-1 and CQD-2 reveal photoluminescence characteristic (**Figure 3b**) with a maximum fluorescence intensity at 450 nm under 380 nm excitation.³⁹ The fluorescence emission is wavelength-dependent (**Figure 3c, 3d**). CQD-1 display a broad (full width at half maximum of around 100 nm) and intense photon emission, while CQD-2 exhibit a lower fluorescence. Increasing the excitation wavelength to 500 nm results in a red-shift of the emission band to 590 nm for CQD-1 and 580 nm for CQD-2, with the fluorescence emission

intensity of CQD-1 being somehow higher than that of CQDs-2. Using quinine sulfate as reference with a quantum yield of 0.54, the fluorescent quantum yields of CDQ-1 and CQD-2 varied between 0.008 and 0.002, respectively (**Table 1, Figure S5**). The long storage stability at 4 °C and effects of parameters such as prolonged UV exposure of CQDs were studied. The fluorescence intensity of CQD-1 had no obvious decrease (14%) after being stored 2-years at 4 °C and effects of parameters such as prolonged UV exposure of CQDs were studied. The fluorescence intensity of CQD-1 had no obvious decrease (14%) after being stored 2-years at 4 °C (**Figure S6**). The fluorescence intensity of CQD-2 had higher decrease (48%). In contrast, the normalized fluorescence intensity before and after 2-years for both CQDs was almost unchanged, which suggest no chemical modifications. CQDs displayed UV-dependent fluorescence behavior. CQD-2 present a relatively stable fluorescence emission intensity during 30 min exposure to UV irradiation (360 nm, 10 mW cm⁻²) in comparison to CQD-1.




Figure 3: (a) UV-vis spectra of CQD-1 and CQD-2 at 20 $\mu\text{g mL}^{-1}$ in PBS (pH 7.4, 0.01 M). (b) Normalized emission (exc. at 378 nm) and normalized excitation (em. 453 nm) spectra of CDQ-1; normalized emission (exc. at 382 nm) and normalized excitation (em. 452 nm) spectra of CQD-2. (c) Emission spectra of CQD-1 at progressively increasing excitation wavelengths from 280 to 500 nm. (d) Emission spectra of CQD-2 at progressively increasing excitation wavelengths from 280 to 500 nm.

2.2. Photothermal properties of CQD-1 and CQD-2

The photothermal properties of CQD-1 and CQD-2 ($50 \mu\text{g mL}^{-1}$) were determined upon irradiation the aqueous solutions with a laser at 810 nm for 15 min. **Figure 4** indicates that in both cases a temperature plateau is reached after 10 min, reaching about 50°C for a laser power of 1 W cm^{-2} and 66°C for 2 W cm^{-2} . However, the same temperature trend is observed with PBS solution, indicating poor photothermal properties of these CQDs under these experimental conditions.




Figure 4: Photothermal properties of CQDs. Temperature profiles of CQDs ($50 \mu\text{g mL}^{-1}$) upon laser irradiation at 810 nm laser at two different power densities: 1 W cm^{-2} (a) and 2 W cm^{-2} (b).

2.3. Metabolic activity and cellular uptake of CQDs

The cell toxicity of CQDs-1 and CQDs-2 was established on ARPE-19 and MIO-M1 cell lines after 8 h and 24 h incubation (**Figure 5**). The CQDs toxicity was evaluated using the resazurin assay, based on the conversion of non-fluorescent dye to a fluorescent molecule by mitochondrial and cytosolic enzymes. All CQDs are non-toxic to ARPE-19 and MIO-M1 cells until $100 \mu\text{g mL}^{-1}$ for 8 h incubation. For longer incubation times, the metabolic activities decrease from $25 \mu\text{g mL}^{-1}$ onwards.

Furthermore, the cell toxicity of CQDs-1 and CQDs-2 was established on HeLa and U-87 MG cell lines (**Figure S7a**). All CQDs are non-toxic to HeLa and U-87 MG cells until $100 \mu\text{g mL}^{-1}$ for both incubation times. HeLa and U-87 MG cells were incubated with CQDs at $100 \mu\text{g mL}^{-1}$ during 24 h and then, nuclei were stained with Hoechst 33258, a fluorescent dye for labeling DNA in fluorescence microscopy (**Figure S7b**). The green fluorescence, which is attributed to the CQDs, is homogeneously distributed in the cytoplasm after 24 h when incubated at 37°C ,

which confirms the adsorption and internalization of positively charged CQDs-2 inside the cells, while there is almost no fluorescence for CQDs-1.




Figure 5: Metabolic activity of CQDs. Metabolic activity of ARPE-19 and MIO-M1 cells treated with CQDs: cells were grown in 96-well plates (10^4 cells/well) with 100 μ L of culture medium containing increasing concentration of CQDs for 8 h (left) and 24 h (right). The results, expressed as percentage of viability, are the mean value of two independent experiments with each treatment performed in triplicate. Negative control: without CQDs.



2.2. Inhibition of type I collagen aggregation with CQD-1 and CQD-2

Fibril formation of type I collagen has been widely studied by some research teams.⁴⁰⁻⁴⁶ Therefore, type I collagen was investigated in this present work to assess to what extent CQDs may inhibit its fibrillation. As explained in the experimental section, fibril formation of type I collagen was initiated by incubating collagen I solution at 37 °C. The change in the optical density of the sample at 313 nm as a function of time was recorded (**Figure 6a**). After a lag time of about 2 min, a collagen self-assembly growth phase was observed, reaching a plateau after about 3 min which is in line with other reports.⁴⁵ AFM imaging (**Figure 6b**) confirmed the formation of collagen fibers, with a typical diameter of ~150 nm.

The presence of a low amount of negatively charged CQD-1 ($< 100 \mu\text{g mL}^{-1}$) mainly influences the lag time i.e. the onset of collagen fibrillation. Through AFM imaging aggregate formation is observed in the presence of $100 \mu\text{g mL}^{-1}$ of CQD-1, with fibers with a diameter of 40-50 nm, much smaller compared with control collagen fibers. A higher CQD-1 concentration of $250 \mu\text{g mL}^{-1}$ resulted in complete inhibition of the collagen fibrillation. In contrast, the presence of a low amount of positively charged CQD-2 induced an acceleration of type I collagen fibril formation (**Figure 6a**). The AFM image of collagen in the presence of $100 \mu\text{g mL}^{-1}$ CQD-2 (**Figure 6b**) indicates a quasi-complete inhibition of fibrillation with isolated aggregates of $1.5 \mu\text{m}$ in length and a diameter of $\sim 50 \text{ nm}$. Note that a complete inhibition of collagen fibrillation was already observed at a concentration of $150 \mu\text{g mL}^{-1}$.

At low CQDs concentration, some collagen fibril assembly remains. This indicates that the inhibitory effect of CQDs on the nucleation step and intermolecular interactions is concentration dependent. CQDs inhibits fibrillation in a mechanism involving an endothermic reaction along with electrostatic and hydrophobic interactions between neighboring molecules. Hydrogen bonds are believed to be the most stabilizing forces prevailing in these proteins. It is, thus, hypothesized that the hydrogen bonds may be formed between carbonyl and carboxylic acid groups present on the surface of CQD-1 and amine and hydroxyl groups of type I collagen.⁴⁷ This might alter the interactive forces between collagen molecules. The main differences between both type of particles is their surface charge and functionalization. Note that physiochemical properties of nanoparticles such as size and surface charge, have been considered as critical factors for their antifibrotic properties.^{48, 49}

(a)



(b)




Figure 6: Collagen I fibril formation and inhibition by CQDs. (a) Absorption (at 313 nm) over time of a collagen I solution (0.3 mg mL^{-1}) incubated at $37 \text{ }^\circ\text{C}$ in the absence and presence of increasing concentrations of CQD-1 and CQD-2; (b) AFM images of collagen I (0.3 mg mL^{-1}) in the absence and presence of $100 \text{ } \mu\text{g mL}^{-1}$ CQD-1 and CQD-2.

2.3. Destruction of type I collagen fibers under pulsed-laser irradiation in the presence of CQDs


We have recently shown that Au NPs, able to trigger the formation of vapor nanobubbles (VNBs) under pulsed-laser irradiation, adhere to type I collagen fibers and can destroy vitreous opacities.¹⁷ Though, different to CQDs, Au NPs do not seem to interfere with collagen fibrillation (**Figure S8**). The destruction of the type I collagen fibers/vitreous opacities is believed to be mechanical: collapsing VNBs induce a mechanical force which breaks down the fibers. To investigate whether a similar effect could be observed with CQD-1 and CQD-2, type I collagen fibers were mixed with CQD-1 or CQD-2 and irradiated with a pulsed-laser at different fluences and wavelengths. Dark field microscopy was used to visualize the collagen fibers before and after laser irradiation.

As seen in **Figure 7a**, applying light fluences of 1.1 and 4.5 J/cm^2 and laser irradiation wavelengths of 488 , 561 and 650 nm , without the use of CQDs, did not destroy the type I collagen fibers. Irradiation of the collagen fibers in the presence of CQD-1 showed the same result: the collagen fibers remained intact (**Figure 7b**). This contrasts to the use of CQD-2 (**Figure 7c**). Light pulses of $<3 \text{ ns}$ at 488 and 561 nm (4.5 J cm^{-2}) clearly destroyed the collagen fibers. Using a higher wavelength of 650 nm did no longer allow the complete destruction of


the fibers, even if 100 pulses were applied (**Figure 7c**). This could be expected as CQD-2 hardly absorbs at 650 nm (**Figure 3a**). Given that the 488 nm laser light might be (more) harmful for ocular tissues (if compared to 561 nm light), we selected 561 nm to continue our experiments on human opacities.

(a)

Laser only



(b)
CQD-1






Figure 7: Dark-field microscopy images of water-dispersed type I collagen fibers. (a) Before and after light illumination with lasers of different intensities and wavelengths (488, 561 and 650 nm). (b) Before and after light illumination with lasers of different intensities and wavelengths (488, 561 and 650 nm) in the presence of negatively charged CQD-1 (0.4 mg mL^{-1}). (c) Before and after light illumination with lasers of different intensities and wavelengths (488, 561 and 650 nm) in the presence of positively CQD-2 (0.4 mg mL^{-1}). Scale bar: $100 \mu\text{m}$. The yellow dotted squares/rectangles indicate the position of the targeted fiber. Dotted circles indicate the position of the laser beam.

While we find that the pulsed-laser irradiation in the presence of CQD-2 totally destroys the aggregates, the same approach is inefficient using CQD-1. This difference may rely on the surface charge of the two nanoparticles, which is negative for CQD-1 and positive for CQD-2 (**Table 1**). The difference in charges could lower the interaction of CQD-1 with the collagen fibers, when compared to CQD-2. Temperature effects could be also involved. However, CQDs show no photothermal activity (**Figure 4**). In spite one can expect higher photothermal effects with gold nanoparticles, no differences in terms of fluence was observed for fiber destruction:

in both cases fluence of 4.5 J/cm² was required for efficient fiber demolition. This can be explained by the relatively small size of both AuNPs and CQDs which cannot trigger formation of vapor nanobubbles in solution but only when they form clusters or in situation where the distance between particles is reduced (as it is likely the case when both AuNPs or CQDs are bound to fibers).

However, inhibition of the fibrillation with both types of CQDs clearly suggests that they can both interact with collagen molecules (**Figure 7a**).

2.4. Assessment of the mobility of CQDs in vitreous by fluorescence recovery after photobleaching (FRAP)

After intravitreal injection, CQDs must keep their mobility to diffuse and their capacity to bind to the target, the vitreous opacities. Although we expected that CQDs, due to their relatively small size (around 10 nm), could diffuse in the bovine vitreous,⁵⁰ we decided to perform FRAP experiments to ensure they were mobile and could therefore reach the opacities after intravitreal injection. Indeed, while CQDs are positively charged and the vitreous net charge is negative, one can expect that they will interact with the glycosaminoglycans and collagen network of the vitreous thus forming aggregates. FRAP is a technique allowing to measure the diffusion coefficients of fluorescent molecules or nanoparticles. Briefly, a laser of strong intensity is applied on the sample and induces its photobleaching. The diffusion of the surrounding (fluorescent) molecules (or particles) into the bleached area can be measured and observed by a progressive increase of fluorescence intensity. Recovery curves can, therefore, be obtained from which diffusion coefficients can be calculated.

As observed in confocal images (**Figure 8a**), fluorescence recovery curves in water and in vitreous (**Figure 8b and c**) indicate that a complete fluorescence recovery occurs in the bleached area. This observation attests that cationic CQDs can diffuse both in water and in bovine vitreous. Their diffusion coefficients in water and vitreous are comparable (31.4 +/- 7.4 $\mu\text{m}^2/\text{s}$ and 32.9 +/- 13.2 $\mu\text{m}^2/\text{s}$, respectively). Our observation suggests that, despite a positive charge, CQDs keep their mobility in vitreous. The diffusion of CQDs can be due to their small size (around 10 nm) allowing diffusion through the meshes of the collagen network whose size are comprised between 500 and 1000 nm.⁵⁰ This result also indicates that, after intravitreal injection, CQD-2 can sufficiently diffuse to bind the opacities.




Figure 8: Diffusion of cationic CQDs. (a) Confocal microscopy images of CQDs (2.2 mg mL^{-1}) before, during ($t=0\text{s}$) and 130s after photobleaching in water and in bovine vitreous. In water (b) and in vitreous (c) fluorescence of recovery as a function of time occurs in the bleaching area indicating that the cationic CQDs have the ability to diffuse both in water and in bovine vitreous. Scale bar = $100 \mu\text{m}$.

2.5. Destruction of human vitreous opacities treated with CQD-2 under pulsed-laser irradiation

Type I collagen fibers were previously used to attest the efficacy of their destruction after treatment with CQD-2 and upon pulsed-laser irradiation. Since the collagen composition, size and shape of vitreous opacities differ from type I collagen fibers, we therefore decided to test our concept on real opacities from human vitreous obtained from patients after vitrectomy. The first observation is that, without treatment with CQDs, no destruction or change in opacities could be observed after 50 pulses at 561 nm using a fluence of 4.5 J/cm^2 , suggesting the laser itself cannot destroy the opacities. However, as shown in **Figure 9**, when vitreous samples were mixed with CQD-2 (0.4 mg mL^{-1}) a clear destruction of the opacities could be observed after 50 pulses (561 nm ; 4.5 J/cm^2). This result is in line with previous observations from some of us at a same wavelength and fluence using 10 nm hyaluronan-coated Au NPs and suggests a similar efficacy.¹⁷




Figure 9: Dark-field microscopy images of human vitreous opacities: Before and after light illumination (20 and 50 pulses) with laser (561 nm, 4.5 J cm^{-2}) in absence or in presence of CQDs-2 (0.4 mg mL^{-1}). Scale bar (for bottom row): $100 \mu\text{m}$. The yellow dotted squares/rectangles indicate the position of the targeted fiber. Dotted circles indicate the position of the laser beam.

3. Conclusion

In this work, we have shown that cationic CQDs could inhibit the fibrillation of type I collagen *in vitro* and destroy type I collagen fibers and human vitreous opacities through the generation of light-induced VNBs at a low fluence (4.5 J/cm^2). While negatively charged CQDs can inhibit collagen fibrillation, they were unable to destroy the collagen fibers at the studied fluences and wavelengths. Interestingly, while Au NPs can generate VNBs and have been reported to destroy vitreous opacities, they did not impact collagen fibrillation. CQDs can promote the destruction of vitreous opacities in a similar manner (fluence, number of pulses) with a capacity to inhibit collagen fibrillation. Thanks to this dual effect (i.e. inhibition and destruction), cationic CQDs become attractive therapeutic tools for the treatment of vitreous opacities by avoiding or postponing their reformation after laser treatment.

Taken together, our results suggest that this dual effect provided by CQDs could be further explored in the context of fibrotic diseases and more generally for diseases involving protein aggregation.

Supporting Information Available

Figure S1: TEM images of CQD-1 (a) and CQD-2 (b)

Figure S2: XPS high resolution spectra of CQD-1 and CQD-2.

Figure S3: Kaiser test for the determination of the presence of primary amine groups: (a) Calibration curve (benzylamine solution from 10 to 100 μM). (b) UV-vis absorption spectra of CQD-2, heated at 100 °C during 10 min, cooled down on ice and further diluted with 1 mL of ethanolic solution (EtOH/water=60:40).

Figure S4: (a) Zeta potential analysis. (b) Photographs of CQDs suspensions (250 $\mu\text{g mL}^{-1}$) after 1 h incubation at 37 °C in water (W), PBS (0.01 M, P) and Dulbecco's Modified Eagle's medium (M).

Figure S5: The relationship between the integrated fluorescence intensity and the absorbance of quinine sulfate (QS), CQD-1 and CQD-2.

Figure S6: Optical stability of CQD-1 (red) and CQD-2 (blue) in various conditions: Fluorescence emission after 2-years, normalized fluorescence emission after 2-years and relative fluorescence emission of CQDs solution (20 $\mu\text{g mL}^{-1}$ in PBS) during UV light irradiation at 360 nm (10 mW cm^{-2}) during 3 hours.

Figure S7: Metabolic activity and CQDs uptake: (a) Metabolic activity of HeLa and U-87 MG cells treated with CQDs: cells were grown in 96-well plates (10⁴ cells/well) with 100 μL of culture medium containing increasing concentration of CQDs for 8 h (left) and 24 h (right). The results, expressed as percentage of viability, are the mean value of two independent experiments with each treatment performed in triplicate. Negative control: without CQDs. (b) Fluorescence microscopy of HeLa and U-87 MG cells treated with 400 $\mu\text{g mL}^{-1}$ of CQDs for 24 h The blue signal corresponds to the nuclei stained with Hoechst 33258, while the green signal is attributed to CQDs. Scale bars = 100 μm .

Figure S8: Fibril formation study of type I collagen using turbidity data: UV-vis absorption evolution of collagen (0.3 mg mL^{-1}) at 313 nm in PBS buffer (pH 7.4) at 37 °C under static condition (blue) and in the presence of increasing concentrations of gold nanoparticles (AuNPs) (10¹¹-10¹³ AuNPs mL^{-1}).

Acknowledgements

Financial support from the Centre National de la Recherche Scientifique (CNRS), the University of Lille is acknowledged. This work was partly supported by the French Renatech network. The authors would also like to acknowledge funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 810685 (DelNam project).

4. Experimental section

4.1. Materials

Glucosamine hydrochloride, ethylenediamine and β -alanine were purchased from Sigma Aldrich Chimie (France) and used as-received.

Samples of human vitreous containing opacities were collected at the VMR Institute for Vitreous Macula Retina (Huntington Beach, CA, USA) from patients undergoing vitrectomy for the treatment of vision-degrading myodesopsia. The study protocol adhered to the Declaration of Helsinki. Prior to surgery, patients gave a written informed consent that has been reviewed and accepted by the ethical committee of Saint Joseph Health Center for clinical research (Irvine, CA, USA). After vitrectomy, the (undiluted) samples were frozen and stored at $-80\text{ }^{\circ}\text{C}$ until further use.

4.2. Synthesis of carbon quantum dots (CQDs) and gold nanoparticles (AuNPs)

4.2.1. Synthesis of CQD-1

Carboxylated CQDs were synthesized according to a modified procedure.³² To a stirring solution of glucosamine hydrochloride (1.00 g, 4.63 mmol) in distilled water (20 mL) in a 30 mL vial G30, β -alanine (0.454 g, 1.1 eq.) was added and stirred to ensure homogeneity. The reactor was then placed in a microwave (Monowave 450, Anton-Parr). The solution was heated under pressure for 2 min from room temperature to $200\text{ }^{\circ}\text{C}$ and then maintained for 1 min at $200\text{ }^{\circ}\text{C}$ under stirring (1200 rpm). The resulting brown solution was centrifuged at $4\text{ }^{\circ}\text{C}$ (10000 g, 10 min) in order to remove big particles. The supernatant was dialyzed against water during 24 h (SpectraPor RC membranes, 1 kDa) and then kept (or lyophilized) to yield a brown solution.

4.2.2. Synthesis of CQD-2

To a stirring solution of glucosamine hydrochloride (1.00 g, 4.63 mmol) in distilled water (20 mL) in a 30 mL vial G30, ethylenediamine (0.307 g, 1.1 eq.) was added and stirred to ensure homogeneity. The reactor was then placed in a microwave (Monowave 450, Anton-Parr). The

solution was heated under pressure for 5 min from room temperature to 200 °C and then maintained for 10 min at 200 °C under stirring (1200 rpm). The resulting brown solution was centrifuged at +4 °C (10000 g, 10 min) in order to remove big particles. The supernatant was dialyzed against water during 24 h (SpectraPor RC membranes, 1 kDa) and then kept (or lyophilized) to yield a brown solution.

4.2.3 Synthesis of hyaluronic acid-functionalized gold nanoparticles (AuNPs)

The synthesis and hyaluronic acid (HA)-coated AuNPs (10 nm) was performed in house, as previously reported.¹⁷ Briefly, HAuCl₄ (in water) and sodium ascorbate (in water) were mixed at equimolar ratios (concentration=0.2 mM, final volume=100 mL) under rapid stirring for at least 1 h. The formed AuNPs were washed by centrifugation (10 min at 13000 g), resuspended in an aqueous solution of HA (2–4 pM), and kept under rotation overnight. HA-coated AuNPs were finally washed by centrifugation, resuspended in water, and stored for further use. The synthesized NPs were characterized by DLS and zeta potential (Zetasizer Nano, Malvern) measurements. The final concentration of the AuNPs was estimated from the extinction of the dispersions as measured at the maximal extinction wavelength (Ext) and the theoretical extinction cross section σ_{EXT} (cm²), as previously reported.¹⁷

4.3. Primary amine quantification using a modified Kaiser test

The amount of primary amine groups on the CQDs was calculated using a spectrophotometric assay based on the modified Kaiser test with the following modifications.⁵¹ Briefly, CQDs-2 were diluted to 0.1 mg mL⁻¹ in milli-Q water. To this solution was added 50 μ L of phenol solution (40 g in 10 mL EtOH), 50 μ L of potassium cyanide (2 mL of KCN solution - 65 mg in 100 mL water - in 100 mL pyridine) and 50 μ L of ninhydrin solution (2.5 g in 50 mL EtOH). The mixture was heated at 100 °C during 10 min, cooled down on ice and further diluted with 1 mL of ethanolic solution (EtOH/water=60/40). The absorption of the mixture was determined in triplicate at 570 nm using a Perkin Elmer Lambda UV/Vis 950 dual-beam spectrophotometer in 10 mm quartz cuvette. Benzylamine solution was used from 10 to 100 μ M to generate the calibration curve.

4.4. Characterizations

Atomic Force Microscopy (AFM): AFM images were recorded in tapping mode on a DimensionTM 3100 (Digital Instruments) in air at a scan rate of 1 Hz, and with an antimony doped *n*-type silicon cantilever (resistivity: 0.01 – 0.025 Ohm.cm, frequency resonance ranging

from 130 to 250 kHz – with a constant stiffness $k \sim 48 \text{ N.m}^{-1}$). Samples were diluted by 15 with filtered PBS, deposited on freshly cleaved mica substrates, dried in air and then rinsed three times with water. Data were analyzed with a Gwyddion software (2.56).

Transmission electron microscopy (TEM): The morphology and sizes of CQDs were characterized using FEI Tecnai G2-20 microscope.

UV-visible measurements: Absorption spectra were recorded from 200 to 800 nm using a Perkin Elmer Lambda UV/Vis 950 dual-beam spectrophotometer in 10 mm quartz cuvette. CQDs were diluted to $20 \mu\text{g mL}^{-1}$ in PBS (pH 7.4, 0.01 M, Gibco®).

Raman spectroscopy: Raman spectroscopy measurements were performed on a LabRam HR Micro-Raman system (Horiba Jobin Yvon) using a 473 nm laser diode as excitation source. CQDs were deposited on a clean silicon wafer. The visible light is focused by a 100× objective. The scattered light is collected from 100 to 4000 cm^{-1} by the same objective in backscattering configuration, dispersed by a 1800 mm focal length monochromator and detected by a CCD camera.

Fourier transform infrared (FT-IR) spectroscopy: FT-IR analyses were performed on Thermo Fisher Scientific Inc. Nicolet 8700, in the frequency range between 650 and 4000 cm^{-1} with a resolution of 6 cm^{-1} . Dried CQDs (around 1 mg) were mixed with potassium bromide powder (200 mg) in an agar mortar. The mixture was pressed into a pellet under 7 tons of load for 10 min, and the spectrum was recorded immediately. An average of 64 scans was carried out for each sample.

X-ray photoelectron spectroscopy (XPS): XPS spectra were recorded on a VG Escalab 220XL spectrometer from Vacuum Generators featuring a monochromatic Al K α X-ray source (1486.6 eV) and a spherical energy analyzer operated in the CAE (constant analyzer energy) mode (CAE = 100 eV for survey spectra and CAE = 40 eV for high-resolution spectra), using the electromagnetic lens mode. The angle between the incident X-rays and the analyzer is 58° and the detection angle of the photoelectrons is 30° .

DLS measurements: The average hydrodynamic diameter and the zeta-potential were recorded on a Zetasizer® Nano ZS (Malvern Instruments S.A., Worcestershire, UK). All the batches were diluted to $200 \mu\text{g mL}^{-1}$ in milli-Q water and analyzed in triplicate at 20°C . The zeta potential of CQDs in milli-Q water ($200 \mu\text{g mL}^{-1}$) was measured at 20°C using a folded zeta capillary cell (DTS1070). Experiments consisted of 15 runs per measurement with an applied voltage of 150 V.

Fluorescence measurements: Emission and excitation fluorescence spectra were recorded between 200-900 nm using a Xenius XC spectrofluorometer (Safas S.A., Monaco).

Fluorescence measurements of CQDs were performed in PBS (pH 7.4, 0.01 M, Gibco®) at 20 $\mu\text{g mL}^{-1}$ (excitation and emission bandwidth=10 nm, step=1 nm, PMT voltage=460 V, ultrascan). For quantum yield measurements, fluorescence emissions were recorded from 350-900 nm with an excitation wavelength of 350 nm (excitation and emission bandwidth=10 nm, step=1 nm, PMT voltage=260 V, ultrascan). Integrated fluorescence emissions were calculated from 365 to 680 nm.

4.5. Measurement of the photothermal properties

The photothermal properties of 50 $\mu\text{g mL}^{-1}$ solutions of CQDs in PBS (pH 7.4, 0.01 M, Gibco®) were determined by using a continuous laser beam at 810 nm (Gbox model, Fournier Medical Solution) at two power densities (1 and 2 W cm^{-2}). The temperature changes were recorded by an infrared camera (FLIR A655sc, IR lens: $f=24.6\text{mm}$ and 25°) and an image analysis software FLIR ResearchIR Max4.

4.6. Biological evaluations

Cell viability assay

The ARPE-19 spontaneously immortalized cell line of human retinal pigment epithelium, the MIO-M1 Müller progenitor cell line, the HeLa cell line derived from cervical carcinoma from a 31-year-old female (ECACC 93021013, Sigma Aldrich Chimie S.a.r.l, St. Quentin Fallavier, France) and the U-87 MG cell line derived from a malignant glioma (ECACC 89081402, Sigma Aldrich Chimie S.a.r.l, St. Quentin Fallavier, France) were cultured and maintained in Dulbecco's Modified Eagle's medium (DMEM, Gibco®) high glucose with 2 mM Glutamine, DMEM/F12 media with 2 mM Glutamine and DMEM supplemented with 10% fetal bovine serum (FBS, Gibco®) and 1% penicillin-streptomycin (Gibco®), respectively, in a humidified incubator at 37 °C and 5% CO₂. Cells were seeded at a density of 10⁴ cells/well in a 96-well plate and grown for 24 h before assay. The culture medium was replaced with a fresh medium that contains the CQDs from 0 to 400 $\mu\text{g mL}^{-1}$. After 24 h, the old medium was aspirated and cells were washed with PBS. The cell viability was evaluated using resazurin cell viability assay. Briefly, 100 μL of the resazurin solution (11 $\mu\text{g mL}^{-1}$) in appropriate media were added to each well and the plate was incubated for 4 h in the humidified incubator. The fluorescence emission of each well was measured at 593 nm (20-nm bandwidth) with an excitation at 554 nm (18-nm bandwidth) using a Cytation™ 5 Cell Imaging Multi-Mode Reader (BioTek Instruments SAS, France). Each condition was replicated three times and the mean fluorescence value of non-exposed cells was taken as 100% cellular viability.

Cell imaging

HeLa and U-87 MG cells were seeded in a 96-well plate at a density of 10^4 cells/well and grown for 24 h before assay. The CQDs solution were diluted in DMEM/10% FBS to a final concentration of $400 \mu\text{g mL}^{-1}$. After 24-hours incubation at 37°C , the cell monolayers were washed three times with PBS and then stained with Hoechst 33258 ($5 \mu\text{g mL}^{-1}$) in PBS in the dark for 5 min. The plates were directly observed using a Cytation™ 5 Cell Imaging Multi-Mode Reader (BioTek Instruments SAS, France) equipped with a 20x objective (Plan Fluorite WD 6.7 NA 0.45). The fluorescence signal was acquired using excitation and emission filter sets for DAPI (exc. 377/50 nm and em. 447/60 nm) and for GFP (exc. 469/35 nm and em. 525/39 nm). All the images were further analyzed by Gen5iPlus 3.04 Imaging Software.

4.7. Collagen fibril formation

Collagen I from rat tail (A10483-01, Gibco®) was dissolved in PBS (pH 7.4, 0.01 M, Gibco®) at 0°C (ice bath) to obtain a final concentration of 0.3 mg mL^{-1} . CQDs at different concentrations were added. Subsequently, the collagen/CQDs solution was homogenized and incubated without stirring during 1 h at 37°C . The fibrillation process was followed by measuring the absorbance/turbidity of the solutions at 313 nm by using a NanoDrop™ One C spectrophotometer (Thermo Scientific). The baseline correction was done just before to start each experiment ($t = 0 \text{ min}$).

4.8. Photoablation of collagen fibers and human vitreous opacities

Photoablation experiments were performed on collagen fibers in water and human vitreous containing opacities. Collagen fibers (0.02 mg mL^{-1}) were mixed with CQDs in water (0.4 mg mL^{-1}) and allowed to equilibrate for 30 min before the experiment. After thawing the human vitreous samples, they were directly mixed with an equal volume of a dispersion of CQDs (typically 0.4 mg mL^{-1} in water). The samples were then allowed to equilibrate for 30 min at room temperature prior to applying (nanosecond) laser pulses.

First, dark-field microscopy imaging was performed to locate and align the nanosecond laser on the collagen fibers or human vitreous opacities in the sample. To generate vapor nanobubbles, 7 ns laser pulses were used. The wavelengths of the laser light were 488 nm, 561 nm or 650 nm. A beam expander (#GBE05-A, Thorlabs) combined with an iris diaphragm (#D37SZ, Thorlabs) was used to adjust the diameter of the laser beam to $150 \mu\text{m}$. The laser pulse energy was

monitored by an energy meter (J-25MB-HE&LE, Energy Max-USB/RS sensors, Coherent) synchronized with the pulsed laser.

4.9. Diffusion experiments in water and bovine vitreous by photobleaching

Fluorescence recovery after photobleaching (FRAP) experiments were performed to determine the mobility of the fluorescent CQDs in water and bovine vitreous. FRAP experiments were performed using a confocal scanning laser microscope (Nikon A1R) equipped with a 10× lens (CFI Plan Apochromat; Nikon, Badhoevedorp, The Netherlands). In a FRAP experiment, fluorescent nanoparticles in a (vitreous) sample are irreversibly bleached in a small area (100 μm) by an intense laser beam. The surrounding particles (i.e. outside of the bleached zone) will diffuse into the photobleached area, leading to a fluorescence recovery over time. Diffusion coefficients (D) can be derived from the rate and amount of recovery of fluorescence in the bleached zone by fitting the data points to appropriate equations.⁵²

For FRAP experiments in water, 5 μL of a water solution of CQD-2 (2.2 mg mL⁻¹) was applied between a microscope slide and a coverslip which were separated by a 120 μm-thick double adhesive spacer (Secure-Seal Spacer; Molecular Probes, Leiden, The Netherlands). For FRAP experiments in bovine vitreous, bovine vitreous was carefully removed from the eye ball (to avoid undesired liquefaction) and 400 μL were carefully cut and transferred into a glass-bottomed dish. 40 μL of a solution of CQD-2 (2.2 mg mL⁻¹) were then injected in the vitreous using a 1 mL syringe equipped with a 21.5G needle and allowed to equilibrate at room temperature for 30 min before performing FRAP experiments.

References

1. L. Vaughan, M. Mendler, S. Huber, P. Bruckner, K. H. Winterhalter, M. I. Irwin and R. Mayne, *J. Cell Biol.*, 1988, **106**, 991–997.
2. P. N. Bishop, *Prog. Retin. Eye Res.*, 2000, **19**, 323–344.
3. P. N. Bishop, D. F. Holmes, K. E. Kadler, D. McLeod and K. J. Bos, *Invest. Ophthalmol. Vis. Sci.* 2, 2004, **45**, 1041-1046.
4. J. Sebag, *Prog. Retin. Eye Res.*, 2020, 100847.
5. J. Sebag and E. Balazs, *Invest. Ophthalmol. Vis. Sci.*, 1989, **30**, 1867–1871.
6. L. Los, R. van der Worp, M. van Luyn and J. Hooymans, *Invest. Ophthalmol. Vis. Sci.*, 2003, **44**, 2828–2833.
7. G. Garcia, M. Khoshnevis, J. Nguyen-Cuu, K. M. P. Yee, J. H. Nguyen, A. A. Sadun and J. Sebag, *Graefe's Arch Clin Exp Ophthalmol* 2018, **256**, 919-925.
8. J. Sebag, *Am. J. Ophthalmol.*, 2011, **152**, 3-4.
9. J. Mamou, C. A. Wa, K. M. Yee, R. H. Silverman, J. A. Ketterling, A. A. Sadun and J. Sebag, *Invest. Ophthalmol. Vis. Sci.*, 2015, **56**, 1611–1617.
10. E. Ankamah, J. Sebag, E. Ng and J. M. Nolan, *Antioxidants* 2020, **9**, 7.
11. J. Sebag, K. M. P. Yee, L. Huang, C. Wa and A. A. Sadun, *Retina*, 2014, **34**, 1062-1068.
12. J. Sebag, K. M. P. Yee, J. H. Nguyen and J. Nguyen-Cuu, *Ophthalmology Retina*, 2018, **2**, 881-887.
13. R. Milston, M. Optoma and M. C. Madigan, *Survey of ophthalmology*, 2016, **61**, 211-227.
14. J. H. Nguyen, J. Nguyen-Cuu, F. Yu, K. M. Yee, J. Mamou, R. H. Silverman, J. Ketterling and J. Sebag, *Ophthalmology Retina*, 2019, **126**, 1517-1526.
15. P. Stalmans, M. S. Benz, A. Gandorfer, A. Kampik, S. Pakola and J. A. Haller, *N Engl J Med.*, 2012, **367**, 606e615.
16. J. Sebag, *Retina*, 2009, **29**, 871-874.
17. F. Sauvage, J. C. Fraire, K. Remaut, J. Sebag, K. Peynshaert, M. Harrington, F. Van de Velde, R. Xiong, M.-J. Tassignon, T. Brans, K. Braeckmans and S. De Smedt, *ACS Nano* 2019, **13**, 8401-8416.
18. K. Nekoueian, M. Amiri, M. Sillanpää, F. Marken, R. Boukherroub and S. Szunerits, *Chem. Soc. Rev.*, 2019, **48**, 4281-4316
19. M.-X. Zhao and B.-J. Zhu, *Nanoscale Res. Lett.*, 2016, **11**, 207.
20. A. Barras, Q. Pagneux, F. Sane, Q. Wang, R. Boukherroubs, H. Didier and S. Szunerits, *ACS Appl. Mater. Interfaces* 2016, **8**, 9004–9013.
21. H.-J. Jian, R.-S. Wu, T.-Y. Lin, Y.-J. Li, H.-J. Lin, S. G. Harroun, J.-Y. Lai and C.-C. Huang, *ACS Nano*, 2017, **11**, 6703-6716.
22. A. Shoval, A. Markus, Z. Zhou, X. Liu, R. Cazelles, I. Willner and Y. Mandel, *Small*, 2019, **15**, 1902776.
23. D. Qu, X. Miao, X. Wang, C. Nie, Y. Li, L. Luo and e. al., *J. Mater. Chem. B*, 2017, **5**, 4988–4992.
24. B. B. Karakoçak, J. Liang, S. Kavadiya, M. Y. Berezin, P. Biswas and N. Ravi, *ACS Appl. Nano Mater.*, 2018, **1**, 3682–3692.
25. C.-Q. Li, X.-Y. Liu, S.-L. Li, P. Jiang, F.-J. Jiang and Y. Liu, *ACS Appl. Bio Mater.*, 2019, **2**, 4067-4076.
26. X. Han, Z. Jing, W.-C. Wu, B. Zou, Z. Peng, P. Ren, A. Wikramanayake, Z. Lu and R. M. Leblanc, *Nanoscale*, 2017, **9**, 12862.
27. S. Li, L. Wang, C. C. Chusuei, V. M. Suarez, P. L. Blackwelder, M. Micic, J. Orbulesu and R. M. Leblanc, *Chem. Mater.*, 2015, **27**, 1764-1771.

28. Y. Q. Q., J. C. Jin, J. Q. Zhang, B. B. Wang and Y. Liu, *J. Mater. Chem. B*, 2017, **5**, 2010-2018.
29. L. Wang, S. Zhu, T. Lu, G. Zhang, J. Xu, Y. Song, Y. Li, L. Wang, B. Yang and F. Li, *J. Mater. Chem. B*, 2016, **4**, 4913-4921 2016.
30. A. Łoczechin, K. Séron, A. Barras, E. Giovanelli, S. Belouzard, Y.-C. Chen, Metzler-Nolte, N. , R. Boukherroub, J. Dubuisson and S. zunerits, *ACS Appl. Mater. Interfaces*, 2019.
31. T. V. de Medeiros, J. Manioudakis, F. Noun, J.-R. Macairan, F. Victoria and R. Naccache, *J. Mater. Chem. C*, 2019, **7**, 7175-7195
32. S. A. Hill, D. Benito-Alifonso, S. A. Davis, D. J. Morgan, M. Berry and M. C. Galan, *Sci. Rep.*, 2018, **8**, 12234
33. S. K. Tammina and Y. Yang, *J. Photoch. Photobiol. A*, 2020, **387**, 112134.
34. S. Chandra, S. Pradhan, S. Mitra, P. Patra, A. Bhattacharya, P. Pramanik and A. Goswami, *Nanoscale*, 2014, **6**, 3647-3655.
35. J.-B. Wu, M.-L. Lin, X. Cong, H.-N. Liu and P.-H. Tan, *Chem. Soc. Rev.*, 2018, **47**, 1822-1873.
36. P. Zhu, K. Tan, Q. Chen, J. Xiong and L. Gao, *Chem. Mater.*, 2019, **31**, 4732-4742.
37. W. Zhang, Y. Wang, X. Liu, X. Meng, H. Xu, Y. Xu, B. Liu, X. Fang, H.-B. Li and T. Ding, *Phys. Chem. Chem Phys.*, 2017, **19**, 28653-28665.
38. H. Peng and J. Travas-Sejdic, *Chem. Mater.*, 2009, **21**, 5563-5565.
39. S. Zhu, Y. Song, X. Zhao, J. Shao, J. Zhang and B. Yang, *Nano Research*, 2015, **8**, 355-381.
40. H.-J. Cjung, A. Steplewski, K. Y. Chung, J. Uitto and A. Fertala, *J. Biol. Chem.*, 2008, **283**, 25879-25889.
41. X. Yin, L. Zhao, S.-g. Kang, J. Pan, Y. Song, M. Zhang, G. Xing, F. Wang, J. Li, R. Zhou and Y. Zhao, *Nanoscale*, 2013, **5**, 7341.
42. K. Rasheeda and N. Fathima, *Colloids Surf. B* 2018, **170**, 273-279.
43. H. Bharathy and N. Nishad Fathima, *Int. J. Biol. Macromol.* 2017, **10**, 179-186.
44. J. Jayamania, R. Ravikanth Reddy, B. Madhand and G. Shanmugama, *Int. J. Biol. Macromol.* 2018, **107**, 175–185.
45. B. G. Anand, K. Dubey and D. S. Shekhawat, *Langmuir*, 2017, **33**, 13252-13261.
46. S. Perumal, K. Dubey, R. Badhwar, K. J. George, R. K. Sharma, G. Bagler, B. Madhan and K. C. Kar, *Eur. Biophys. J.*, 2015, **44**, 69–76.
47. H. S. Frederick, W. F. Joseph and P. S. Gurinder, *J. Biomech.* , 2003, **36**, 1529–1553.
48. Y. Kim, J.-H. Park, H. Lee and J.-M. Nam, *Sci. Rep.*, 2016, **6**, 1.
49. F. Sauvage, J. Schymkowitz, F. Rousseau, B. Z. Schmidt, K. Remaut, K. Braeckmans and S. C. De Smedt, *Nano Today*, 2020, **31**, 100837.
50. S. Xu, N. J. Boylan, J. S. Suk, Y.-Y. Wang, E. A. Nance, J.-C. Yang, P. J. McDonnell, R. A. Cone, E. J. Duh and J. Hanes, *J. Control. Release*, 2013, **167**, 76-84.
51. G. Jarre, S. Heyer, E. Memmel, T. Meinhardt and A. Krueger, *Beilstein Journal of Organic Chemistry*, 2014, **10**, 2729-2737.
52. T. K. L. Meyvis, S. S. De-Smedt, P. Van-Oostveldt and J. Demeester, *Pharm Res.* , 1999, **16**, 1153–1162.